Search Results

are conserved adhesion G protein-coupled receptors; they are essential for embryogenesis and neural development We employ cellular assays with full-length CELSR1 and truncation constructs to assess the adhesive and

About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Developing During her time at Providence College, she received the Walsh Grant Fellowship to develop novel methods

Sokhom recalls how binding assays at BMS introduced him to the depth and complexity of receptor pharmacology

Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools

<< Back to podcast list Strategic Partner(s) Developing new tools to uncover GPCR signaling patterns My particular projects revolve around developing new tools to study GPCR activity in ways that were not This research has led to a first-author Cell article on the development of a new biosensor platform called Overall, the lab works on diverse models and diseases, and has developed a wide array of tools to dissect

I hope to develop my skillsets so as to be able to establish my own lab in future to work on adhesion Recent studies implicate the dysregulation of adhesion G-Protein coupled receptors (GPCRs) in GBM development A mouse model of Zhu-Tokita-Takenouchi-Kim syndrome reveals indispensable SON functions in organ development This research focuses on the design of a new endogenous ADGRB1 activation reporter assay to test analogs About Jesse Stillwell "Jesse Stillwell is a 3rd year graduate student with a research focus in drug development

Home → Flash News → 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs GPCR Courses 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”!

Home → Flash News → 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

Home → Flash News → 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

“Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

Home → Flash News → In case you haven’t heard, registrations are open for the next 4-week course “Development with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs GPCR Courses In case you haven’t heard, registrations are open for the next 4-week course “Development with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

. 🚀 Develop New GPCR Skills Join Dr. Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential insights into: 🔹 Drug Development Basics – PK-PD insights, absorption, and drug properties 🔹 Clearance He discusses biased signaling in GPCR research, developing biosensors for G protein activity, networking light-sensitive GPCR, bistable opsin Diapause hormone receptor affects larval growth and embryonic development

🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development

His thesis work led to the development and application of light energy transfer methodology to study His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway biotech companies, ModMab Therapeutics , and AntlerA Therapeutics , which are pursuing the clinical development

At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational serves as board chair at Radionetics Oncology, a pharmaceutical company focused on the discovery and development

The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers Cardarelli is a drug development leader with extensive experience driving drug discovery teams in bringing biology, pharmacology, translational medicine, oncology, immuno-oncology, immunology, and clinical development While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic development

aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing Novoprotein developed a NovoiSMART technology, utilizing mRNA-based immunization, which can overcome These examples underscore the potential of NovoiSMART technology in developing highly specific antibodies

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

As a developer, and more recently the lead developer of GPCRdb my day-to-day work centers around the maintenance and resource/tool development of GPCRdb and its sister databases.

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Gebhard Schertler, he developed methods for kinetic mathematical analysis of GPCR signaling. Before focusing on the development of innovative mathematical modeling and simulation methods for drug Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery of interdisciplinary teamwork in drug and technology development, noting the challenges of communication

led me to the Ottawa Hospital Research Institute (then the Moses and Rose Loeb Research Institute) to develop We are also currently developing the translational component of our research to capitalize on the druggability We hope our research will aid in the development of new therapeutic interventions for the alleviation

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April GPCRs GPCR Events, Meetings, and Webinars March 19, 2025 | Advancing obesity drug discovery: Cell-based assays

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

these benefits are designed to enhance your research experience and keep you informed about the latest developments year • per person • 90% discount *subject to verification Eligibility Criteria ✔ Live and work in a developing country. ✔ Be employed by an institution, university, or company based in a developing country. ✔ Provide Do you offer discounts for students or developing countries? Yes. Members from developing countries can join for $24.99/year.

I have 10 years of experience in the development and management of R&D projects and teams in the field I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences

About Joshua Gross "I am a neuropharmacologist interested in exploiting GPCR biased signaling to design/develop With my expertise in reward behavior, neurophysiology, GPCR signaling, and preclinical drug development , my lab will strive to develop novel GPCR pharmacotherapies that improve efficacy and minimize side

Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development